Logo

Transgenomic Extends Supply Agreement with Geron for Nucleic Acid Building Blocks

Apr 20, 2005

NEW YORK, April 20 (GenomeWeb News) - Transgenomic will supply Geron with additional modified nucleic acid reagents to synthesize an anti-cancer drug, the Omaha, Neb.-based company said today.

 

The additional shipments, which add to an existing supply agreement between the two companies, will be completed later this year.

 

Geron's cancer drug is a thio-phosporamidate oligonucleotide, for which Transgenomic provides the building blocks.

Breaking News
The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.